Articles published by Rejoni, Inc.

Rejoni Showcases FDA-Approved Juveena® Hydrogel System at AAGL 2026 Global Congress in Boston Alongside Pivotal Trial Results Published in Fertility and Sterility

November 13, 2026

From Rejoni, Inc.

Via Business Wire

Rejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis

September 29, 2026

From Rejoni, Inc.

Via Business Wire

Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch

June 16, 2026

From Rejoni, Inc.

Via Business Wire

Rejoni Appoints Women’s Health MedTech Leader John Nealon as Chief Executive Officer

May 04, 2026

From Rejoni, Inc.

Via Business Wire

FDA Files Rejoni’s Juveena® Hydrogel System PMA for the Prevention of Intrauterine Adhesions

January 13, 2026

From Rejoni, Inc.

Via Business Wire

Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.

February 04, 2025

From Rejoni, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.